Insulin Analogues with Increased Mitogenic Potency - Are they Safe?

Abbreviations

HMEC

Human Mammary Epithelial Cells

IGF1

Insulin-like growth factor-1

IGF1R

Insulin-like growth factor-1 receptor

Insulin Aspart

B28Asp human insulin

Insulin Detemir

B29Lys(ε-tetradecanoyl), desB30 human insulin

Insulin Glargine

A21Gly,B31Arg,B32Arg human insulin

Insulin Glulisine

B3Lys,B29Glu human insulin

Insulin LisPro

B28Lys,B29Pro human insulin

IR

Insulin receptor

References

• 1 Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus.  Drugs. 2005;  65 325-340
• 2 Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action.  Nat Rev Mol Cell Biol. 2006;  7 85-96
• 3 Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake.  Diabetes Metab Rev. 1992;  8 259-286
• 4 Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C. et al . Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.  Diabetes. 2000;  49 999-1005
• 5 Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH. et al . Sustained signaling from the insulin-receptor after stimulation with insulin analogs exhibiting increased mitogenic potency.  Biochem J. 1996;  315 271-279
• 6 Liefvendahl E, Arnqvist HJ. Mitogenic Effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-1.  Horm Metab Res. 2008 April 07, [Epub ahead of print]; 
• 7 Slieker LJ, Brooke GS, Dimarchi RD, Flora DB, Green LK, Hoffmann JA. et al . Modifications in the b10-region and b26-30-region of the b- chain of human insulin alter affinity for the human igf-i-receptor more than for the insulin-receptor.  Diabetologia. 1997;  40 S54-S61
• 8 Staiger K, Hennige AM, Staiger H, Haering HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells.  Hormone Met. 2007;  39 65-67
• 9 Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.  Int J Toxicol. 2002;  21 171-179
• 10 Kuerzel GU, Shukla U, Scholtz HE, Pretorius SG, Wessels DH, Venter C. et al . Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.  Curr Med Res Opin. 2003;  19 34-40
• 11 Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU. The long-acting human insulin analog hoe-901 - characteristics of insulin signaling in comparison to asp(b10) and regular insulin.  Hormone Met. 1998;  30 123-129
• 12 Bahr M, Kolter T, Seipke G, Eckel J. Growth-promoting and metabolic-activity of the human insulin analog [gly(a21),arg(b31),arg(b32)]insulin (hoe-901) in muscle-cells.  Eur J Pharmacol. 1997;  320 259-265
• 13 Kohn WD, Micanovic R, Myers SL, Vick AM, Kahl SD, Zhang LS. et al . pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.  Peptides. 2007;  28 935-948
• 14 Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: Comparisons to insulin and IGF-I.  J Clin Endocrinol Metab. 2001;  86 5838-5847

Correspondence